DelMar Pharmaceuticals to Host Key Opinion Leader Summit on Glioblastoma Multiforme and the Potential for Treatment with VAL-083 November 5, 2019 • 8:30 AM EST
DelMar Pharmaceuticals to Present Updates of Two Phase 2 Clinical Trials of VAL-083 at the 2019 Society for NeuroOncology Annual Meeting October 29, 2019 • 8:30 AM EDT
DelMar Pharmaceuticals to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference October 24, 2019 • 8:30 AM EDT
DelMar Pharmaceuticals to Present at the Inaugural MicroCap Rodeo Investor Conference on October 15, 2019 at 11:30 AM Central Time October 10, 2019 • 8:30 AM EDT
DelMar Pharmaceuticals to Present at the Fall Investor Summit on September 16, 2019 September 11, 2019 • 8:00 AM EDT
DelMar Pharmaceuticals Announces Fiscal Year 2019 Financial Results and Recent Corporate Updates September 10, 2019 • 8:00 AM EDT
DelMar Pharmaceuticals Reports Full Compliance with Nasdaq Listing Criteria September 9, 2019 • 8:00 AM EDT
DelMar Pharmaceuticals Relocates Headquarters to San Diego, California September 4, 2019 • 8:30 AM EDT
DelMar Pharmaceuticals Anticipates Current Cash Runway Will Provide Sufficient Capital for Full Enrollment in All Three Patient Groups in Two Phase 2 Clinical Trials August 27, 2019 • 8:30 AM EDT
DelMar Pharmaceuticals Announces Pricing Of $6.8 Million Underwritten Public Offering August 14, 2019 • 9:10 AM EDT